Future Science Group
crc-2022-0002 Suppl.docx (21.94 kB)

Supplemental Data: Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer

Download (21.94 kB)
posted on 2022-11-09, 10:59 authored by Tanios S. Bekaii-Saab, Sigrid Balser, Ragna Lohmann, Hasan Daoud, Bernd Liedert, Dorothee Schliephake

Supplemental Data: Full inclusion criteria and full exclusion criteria. 


Study 1302.3 was funded by Boehringer Ingelheim GmbH. The authors received no direct compensation related to the development of the manuscript. TS Bekaii-Saab: Agios, Arys, Arcus, Atreca, Boston Biomedical, Bayer, Eisai, Celgene, Lilly, Ipsen, Clovis, Seattle Genetics, Genentech, Novartis, Mirati, Merus, Abgenomics, Incyte, Pfizer, BMS (RF–institution), Ipsen, Arcus, Pfizer, Seattle Genetics, Bayer, Genentech, Incyte, Eisai, and Merck (C/A–institution), Stemline, AbbVie, Boehringer Ingelheim, Janssen, Daichii Sankyo, Natera, TreosBio, Celularity, Exact Science, Sobi, BeiGene, Kanaph, AstraZeneca, Deciphera, MJH Life Sciences, Aptitude Health, Illumina, and Foundation Medicine (C/A–self), Fibrogen, Suzhou Kintor, AstraZeneca, Exelixis, Merck/Eisai, PanCan, and 1Globe (IDMC/DSMB–self), Imugene, Immuneering, Xilis, Replimune, and Sun Biopharma (SAB), Uptodate (Royalties), WO/2018/183488 and WO/2019/055687 (Inventions/Patents); S Balser: Boehringer Ingelheim (E); R Lohmann: Boehringer Ingelheim (E); H Daoud: Boehringer Ingelheim (E); B Liedert: Boehringer Ingelheim (E–former); D Schliephake: Boehringer Ingelheim (E). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Writing, editorial support and formatting assistance was provided by Ken Sutor, contracted by Ashfield MedComms, an Inizio company, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). BIPI was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations. (C/A) Consulting/advisory relationship; (RF) Research Funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (OI) Ownership Interests; (IP) Intellectual property rights/Inventor/patent holder; (SAB) Scientific advisory board; (IDMC/


Usage metrics

    Future Science Group



    Ref. manager